Latest news

• Clovis rockets on maintenance data in ovarian cancer

  Another candidate - AbbVie's veliparib - failed two phase III trials in April (in breast and lung cancer) and now looks unlikely to challenge the leaders.

• AbbVie's PARP inhibitor veliparib fails to deliver

  Unfortunately, the data does not support the use of veliparib in combination with chemotherapy in these patients.". ... analysts at Jefferies veliparib was only seen as a minor component of that effort given the increasingly crowded PARP inhibitor market.

• Tesaro's niraparib threatens Lynparza after acing ovarian cancer trial

  With Lynparza's use limited to BRCA-positive patients and AbbVie's veliparib and Pfizer's talazoparib being studied initially for breast cancer, Tesaro could be on its own in the

• Another NICE no for AZ’s new ovarian cancer drug

  Last year, Lynparza is the first drug in the class to be approved for marketing, beating rivals such as Merck &Co/Tesaro's niraparib and AbbVie's veliparib which are in

• AZ's Lynparza cleared for ovarian cancer in Europe

  rivals such as Merck &Co/Tesaro's niraparib and AbbVie's veliparib which are in phase III testing in ovarian and breast cancer, respectively.